The AREDS 1 and 2 studies provide important information about the role of ocular nutrition in macular degeneration. However, to benefit patients, the findings must be condensed into clear and concise advice that will help them select appropriate vitamin supplements and follow a healthy lifestyle.
A single, 1.0 or 2.0 mg intravitreal injection of the designed ankyrin repeat protein (DARPin) MP0112 showed promising efficacy and long-term duration in a trial of patients with age-related macular degeneration (AMD).
Bayer HealthCare has applied to the EMA for marketing authorization of aflibercept solution for injection for the treatment of patients with visual impairment caused by macular oedema secondary to BRVO.
Taking vasodilators may increase the risk of developing early-stage age-related macular degeneration (AMD), according to a study published online.
Patients who have macular oedema secondary to branch retinal vein occlusion (BRVO) see improved anatomic and functional outcomes with combined intravitreal bevacizumab (IVB) and intravitreal triamcinolone acetate (IVT) therapy when it is delivered early in the disease process, according to the findings of recently published research.
Dry age-related macular degeneration (AMD) is the most common cause of vision loss in developed countries. Although anti-VEGFs can be used to improve the quality of life for patients with the wet form of the disease there is still not much to offer dry AMD patients. In this article, Dr Georgiou highlights the results of his recent study looking at the value of higher doses of omega-3 fatty acids for this group of patients.
In this article, the authors present the highlights of their research into a new blade design for pars plana vitrectomy.
Numerous trials assessing the efficacy and safety of anti-VEGFs in adults exist, however, the clinical evidence and basic science research of anti-VEGF use in infants is lacking, according to Dr Drenser. Here, she discusses what is required from future studies to justify the use of anti-VEGFs in young patients.
ALG-1001 is the first of a new class of drugs, integrin peptide therapy, now going through clinical trials for patients with age-related macular degeneration, diabetic macular oedema and vitreomacular traction.
In this article, the authors summarize a recently published case study of a macular hole formation and its spontaneous closure after vitrectomy.
With a greater understanding of how ocular nutrition affects sight, ophthalmologists need to encourage healthy diets with nutrients and antioxidants essential for healthy vision.
Scleral buckling or pars plana vitrectomy (PPV) can be used to treat rhegmatogenous retinal detachment (RD) associated with Beh?et's disease (BD), according to researchers in the Department of Ophthalmology, Zagazig University, Egypt.
The correlation between hyperglycaemia and retinopathy of prematurity (ROP) is significant, according to logistical regression analysis of gestational age and birth weight data in a recent study.
A tetracycline-inducible Cre mouse line created specifically to study the retinal pigment epithelium (RPE) is suitable for Cre/lox-based gene activation and inactivation in adult RPE, which makes the mice suitable for long-term studies requiring conditional gene targeting.
The natural history of diabetic retinopathy is modified by long-term treatment with intravitreal ranibizumab, reports one ophthalmologist.
In this piece, Dr Manish Nagpal describes his experience and treatment protocol using pattern-scanning laser to manage DME patients, highlighting the benefits of targeted laser application and discussing a case where DME was resolved successfully.
Urgent vitrectomy/phacovitrectomy to treat retinal detachment will produce the best postoperative visual acuity when it is conducted within 2 days or less of the detachment, according to a recent study.
During a press briefing held at the 4th COPHy congress in Budapest, Hungary, key opinion leaders discussed VMT and macular holes and how a new injectable drug could benefit patients. In this article, we will present the highlights of this meeting.
A new agent aimed at treating symptomatic vitreomacular adhesion may lead to variable outcomes based on several pre-treatment patient characteristics.
Treatment of diabetic macular oedema (DME) with ranibizumab may improve retinal function and structure, according to researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College, London Institute of Ophthalmology.
According to Prof. Lois, peeling the internal limiting membrane when operating on patients with idiopathic full-thickness macular hole improves the outcomes of surgery. This article reviews her recent review study and highlights the outcomes.
The membranes found on the retinal surface can cause visual symptoms in various conditions and a patient's vision can often be improved with surgical removal of these membranes, according to Mr Mahmut Dogramaci (The Lister Surgicentre, Lister Hospital, Stevenage, UK).
Ultra-widefield fluorescein angiography may help improve treatment in patients with recalcitrant diabetic macular oedema by visualizing areas of peripheral nonperfusion that can benefit from targeted photocoagulation.
This article discusses the prognostic factors and options in the surgical management of rhegmatogenous retinal detachments associated with macular holes.
According to this article, not all patients may benefit from routine testing prior to surgery. A better option may be selective screening for those at greatest risk for adverse systemic events.
